FDA accepts GSK’s Jemperli application for rectal cancer
GSK announced the FDA accepted its application for priority review of Jemperli (dostarlimab) to treat certain rectal cancer patients. The PDUFA action date is February 2027, with potential for earlier review. The application is based on the AZUR-1 trial, which met its primary objective. Jemperli is not yet approved for this indication. GSK acquired the drug through its purchase of TESARO, which licensed it from AnaptysBio.
How this was made
The 30-second read
Why it matters
Regulatory acceptance signals a possible new market for GSK, but actual approval depends on forthcoming data review.
Market read
The news could drive short-term GSK stock movement and influence biotech sector sentiment.
What to watch
Future competition from other MSI-H rectal cancer therapies could limit upside.
Background
GSK's Jemperli (dostarlimab) previously held Fast Track and Breakthrough designations; this is the first FDA acceptance for rectal cancer indication.
Ticker impact
FDA accepted GSK's Jemperli supplemental BLA for priority review, assigning a PDUFA date of Feb 2027.
moderate upside if trial data holds up
First report of priority review for a new indication; market typically reacts positively to FDA acceptance.
Market effects
Potentially strengthens oncology pipeline perception for GSK and peers.
UK and US markets may see modest GSK share movement.
Adds to broader biotech regulatory sentiment globally.
Counterpoint
If trial data fails to meet expectations, the priority review may not translate into price gains.
Key entities
- companyGSK plc
Global pharmaceutical company seeking FDA approval for Jemperli in rectal cancer.
- regulatorFDA
U.S. Food and Drug Administration reviewing the supplemental BLA.
